Symptoms and Endoscopic Results in Consideration of Pretreatment
1 other identifier
observational
16,255
0 countries
N/A
Brief Summary
Under daily routine conditions and without any intervention by the sponsor regarding the selection of subjects, diagnostic procedures, therapeutic decisions (medicinal and non- medicinal therapy, dose, duration, etc.), routine assessments, the participating physicians (i.e. gastroenterologists) are asked to document relevant data in patients with gastrointestinal disorders.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
September 1, 2005
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 1, 2005
CompletedFirst Submitted
Initial submission to the registry
January 28, 2008
CompletedFirst Posted
Study publicly available on registry
February 11, 2008
CompletedFebruary 11, 2008
January 1, 2008
3 months
January 28, 2008
February 8, 2008
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
to gain insight into the relationship between subjective gastrointestinal symptoms and findings of a laryngopharyngeal-esophagogastric endoscopy with respect to the medicinal pre-therapy;
Secondary Outcomes (1)
to gain insight into the currently used treatment strategies with esomeprazole depending on endoscopic findings.
Study Arms (1)
1
patients with gastrointestinal disorders who need an endoscopy.
Eligibility Criteria
gastroenterologists; specialists
You may qualify if:
- patients with gastrointestinal disorders who need an endoscopy.
You may not qualify if:
- limitiations; possible risks; warnings; contraindications mentioned in the SPC.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- AstraZenecalead
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- STUDY CHAIR
Kai Richter, MD
Medical Department AstraZeneca Germany
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- INDUSTRY
Study Record Dates
First Submitted
January 28, 2008
First Posted
February 11, 2008
Study Start
September 1, 2005
Primary Completion
December 1, 2005
Last Updated
February 11, 2008
Record last verified: 2008-01